Literature DB >> 24616317

Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: less cost at the expense of more genitourinary toxicity is a concerning but testable hypothesis.

Anthony V D'Amico1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24616317     DOI： 10.1200/JCO.2014.55.2380

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Stereotactic body radiation therapy as a derivative of stereotactic radiosurgery: clinically independent but with enduring common themes.

Authors:  Brian D Kavanagh
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

2.  Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.

Authors:  Amar U Kishan; Audrey Dang; Alan J Katz; Constantine A Mantz; Sean P Collins; Nima Aghdam; Fang-I Chu; Irving D Kaplan; Limor Appelbaum; Donald B Fuller; Robert M Meier; D Andrew Loblaw; Patrick Cheung; Huong T Pham; Narek Shaverdian; Naomi Jiang; Ye Yuan; Hilary Bagshaw; Nicolas Prionas; Mark K Buyyounouski; Daniel E Spratt; Patrick W Linson; Robert L Hong; Nicholas G Nickols; Michael L Steinberg; Patrick A Kupelian; Christopher R King
Journal:  JAMA Netw Open       Date:  2019-02-01

3.  Propensity score matched comparison of SBRT versus IMRT for the treatment of localized prostate cancer.

Authors:  Caspian Oliai; Matthew Bernetich; Luther Brady; Jun Yang; Alexandra Hanlon; John Lamond; Steven Arrigo; Michael Good; Michael Mooreville; Bruce Garber; Rachelle Lanciano
Journal:  J Radiat Oncol       Date:  2016-01-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.